Regenxbio initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen initiated coverage of Regenxbio with a Buy rating and $36 price target. The company is focused on the development of gene therapies that enable the production of therapeutic proteins or antibodies for ophthalmic disorders and rare diseases, the analyst tells investors in a research note. The analyst says two pivotal trials of ABBV-RGX-314 in wet advanced neovascular are slated to report topline data in 2025.